These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
182 related items for PubMed ID: 6694560
1. Inhibition of carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats. Rösen P, Reinauer H. Metabolism; 1984 Feb; 33(2):177-85. PubMed ID: 6694560 [Abstract] [Full Text] [Related]
2. Influence of the carnitine palmitoyltransferase inhibitor POCA on myocardial performance and metabolism of insulin resistant rats. Rösen P, Reinauer H. Acta Physiol Hung; 1988 Feb; 71(2):271-80. PubMed ID: 3389170 [Abstract] [Full Text] [Related]
7. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Lopaschuk GD, Spafford M. Circ Res; 1989 Aug; 65(2):378-87. PubMed ID: 2526694 [Abstract] [Full Text] [Related]
13. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Circ Res; 1988 Dec; 63(6):1036-43. PubMed ID: 3197271 [Abstract] [Full Text] [Related]
14. Decrease of fatty acid oxidation, ketogenesis and gluconeogenesis in isolated perfused rat liver by phenylalkyl oxirane carboxylate (B 807-27) due to inhibition of CPT I (EC 2.3.1.21). Wolf HP, Engel DW. Eur J Biochem; 1985 Jan 15; 146(2):359-63. PubMed ID: 4038486 [Abstract] [Full Text] [Related]
15. Effects of sodium 2-[5-(4-chlorophenyl)pentyl]-oxirane-2-carboxylate (POCA) on intermediary metabolism in isolated rat-liver cells. Vaartjes WJ, De Haas CG, Haagsman HP. Biochem Pharmacol; 1986 Dec 01; 35(23):4267-72. PubMed ID: 3790153 [Abstract] [Full Text] [Related]
17. Effects of the acylcarnitine-transferase blocking agent sodium 2[5-(4-chlorophenyl)-pentyl]-oxirane-2-carboxylate (POCA) on metabolism and regional function in the underperfused canine myocardium. Seitelberger R, Kraupp O, Winkler M, Brugger G, Raberger G. J Cardiovasc Pharmacol; 1985 Dec 01; 7(2):273-80. PubMed ID: 2581080 [Abstract] [Full Text] [Related]
18. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity. Bhuiyan AK, Bartlett K, Sherratt HS, Agius L. Biochem J; 1988 Jul 15; 253(2):337-43. PubMed ID: 3178716 [Abstract] [Full Text] [Related]
19. Metabolic changes in fed rats caused by chronic administration of ethyl 2[5(4-chlorophenyl)pentyl]oxirane-2-carboxylate, a new hypoglycaemic compound. Koundakjian PP, Turnbull DM, Bone AJ, Rogers MP, Younan SI, Sherratt HS. Biochem Pharmacol; 1984 Feb 01; 33(3):465-73. PubMed ID: 6231030 [Abstract] [Full Text] [Related]
20. Effects of sodium 2-[5-(4-chlorophenyl)pentyl]-oxirane-2-carboxylate (POCA) on carbohydrate and fatty acid metabolism in liver and muscle. Schudt C, Simon A. Biochem Pharmacol; 1984 Nov 01; 33(21):3357-62. PubMed ID: 6437406 [Abstract] [Full Text] [Related] Page: [Next] [New Search]